The effect of various vitamin D supplementation regimens in breast cancer patients

Luke J PEPPONE; Yousef ZAKHARIA; Alissa J HUSTON; Mary E REID; Randy N ROSIER; Donald L TRUMP; Karen M MUSTIAN; Michelle C JANELSINS; Jason Q PURNELL; Gary R MORROW

doi:10.1007/s10549-011-1415-4

Back

The effect of various vitamin D supplementation regimens in breast cancer patients

Journal article

Peer reviewed

The effect of various vitamin D supplementation regimens in breast cancer patients

Luke J PEPPONE, Yousef ZAKHARIA, Alissa J HUSTON, Mary E REID, Randy N ROSIER, Donald L TRUMP, Karen M MUSTIAN, Michelle C JANELSINS, Jason Q PURNELL and Gary R MORROW

Breast cancer research and treatment, Vol.127(1), pp.171-177

2011

DOI: 10.1007/s10549-011-1415-4

PMCID: PMC3085185

PMID: 22446898

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/3085185View

Open Access

Abstract

Vitamin D deficiency in the patients treated for breast cancer is associated with numerous adverse effects (bone loss, arthralgia, and falls). The first aim of this study was to assess vitamin D status, determined by 25-OH vitamin D levels, among women diagnosed with breast cancer according to demographic/clinical variables and bone mineral density (BMD). The second aim of this study was to evaluate the effect of daily low-dose and weekly high-dose vitamin D supplementation on 25-OH vitamin D levels. This retrospective study included 224 women diagnosed with stage 0–III breast cancer who received treatment at the James P. Wilmot Cancer Center at the University of Rochester Medical Center. Total 25-OH vitamin D levels (D2 + D3) were determined at baseline for all participants. Vitamin D deficiency was defined as a 25-OH vitamin D level < 20 ng/ml, insufficiency as 20–31 ng/ml, and sufficiency as ≥32 ng/ml. BMD was assessed during the period between 3 months before and 6 months following the baseline vitamin D assessment. Based on the participants’ baseline levels, they received either no supplementation, low-dose supplementation (1,000 IU/day), or high-dose supplementation (≥50,000 IU/week), and 25-OH vitamin D was reassessed in the following 8–16 weeks. Approximately 66.5% had deficient/insufficient vitamin D levels at baseline. Deficiency/insufficiency was more common among non-Caucasians, women with later-stage disease, and those who had previously received radiation therapy (P < 0.05). Breast cancer patients with deficient/insufficient 25-OH vitamin D levels had significantly lower lumbar BMD (P = 0.03). Compared to the no-supplementation group, weekly high-dose supplementation significantly increased 25-OH vitamin D levels, while daily low-dose supplementation did not significantly increase levels. Vitamin D deficiency and insufficiency were common among women with breast cancer and associated with reduced BMD in the spine. Clinicians should carefully consider vitamin D supplementation regimens when treating vitamin D deficiency/insufficiency in breast cancer patients.

Tumors

Gynecology. Andrology. Obstetrics

Mammary gland diseases

Biological and medical sciences

Medical sciences

Details

Title: Subtitle: The effect of various vitamin D supplementation regimens in breast cancer patients
Creators: Luke J PEPPONE - Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642, United States
Yousef ZAKHARIA - Department of Medicine, University of Rochester, Rochester, United States
Alissa J HUSTON - Department of Medicine, University of Rochester, Rochester, United States
Mary E REID - Department of Medicine, Roswell Park Cancer Institute, Buffalo, United States
Randy N ROSIER - Department of Orthopaedics, University of Rochester, Rochester, United States
Donald L TRUMP - Department of Medicine, Roswell Park Cancer Institute, Buffalo, United States
Karen M MUSTIAN - Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642, United States
Michelle C JANELSINS - Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642, United States
Jason Q PURNELL - Health Communication Research Laboratory, Washington University, St. Louis, United States
Gary R MORROW - Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642, United States
Resource Type: Journal article
Publication Details: Breast cancer research and treatment, Vol.127(1), pp.171-177
DOI: 10.1007/s10549-011-1415-4
PMID: 22446898
PMCID: PMC3085185
NLM abbreviation: Breast Cancer Res Treat
ISSN: 0167-6806
eISSN: 1573-7217
Publisher: Springer
Language: English
Date published: 2011
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984094320002771

Metrics

13 Record Views